The medical jargon is "greek" to me. Can someone interpret the findings of the last two press releases on Myriad's AZIXIA and their HIV candidate? Are the prospects looking good? What will be the timelines from here? I noticed they brought on a new board member back in September, Dr. Franson, a former Ely Lilly employee... I MYRX working on creating a possible partnership with Ely Lilly? Any insight into this would be greatly appreciated. I'm trying to understand why the company is still trading well below cash.
Thanks for reminding us. It sounds like detailed phase 1/2 results for Azixa+Carboplatin against GBM may be out in a couple of months. Only failure or a miracle would really be opinion-changing results at this stage, but information beats lack of information.
The Azixa results were just a little short of miraculous. Unfortunately, that means the approval process is likely to be pretty standard. Eventual success is likely, emphasis on 'eventual' when you're talking about a little company. On the other hand, 'success' may possibly be huge (with a label for melanoma metastatic to the brain, the drug will surely be used off-label for many other tumors metastatic to the brain. Growth of brain metastases is a common terminal event in cancer). (say about 2 1/2 years to income)
The HIV results were good, but because there are already several good drug combinations available, the approval time-scale and the eventual market are a bit unclear.
Comparing those with today's news of acquisition of a late-development-stage pain-killer: you can sell drugs for terminal cancer to a limited number of specialist physicians; pain drugs require a bigger sales force. A pain drug mostly makes sense for a small company if it plans to be taken over by a biggie.
Looking a little more into what JAV is about: Dyloject is a novel way of delivering a relatively old drug as a clear injectable solution. It is possible that MYRX may be as interested in the technology for preparing dosage forms as in the drug itself. I seem to recall that Azixa is delivered by infusion over several hours, which isn't a popular way to administer drugs.